Cargando…
The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
BACKGROUND: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette–Guerin (BCG). We compared the response, to treatment with BCG, o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791377/ https://www.ncbi.nlm.nih.gov/pubmed/27014622 http://dx.doi.org/10.3389/fonc.2016.00043 |
_version_ | 1782421074525290496 |
---|---|
author | Gofrit, Ofer N. Yutkin, Vladimir Shapiro, Amos Pizov, Galina Zorn, Kevin C. Hidas, Guy Gielchinsky, Ilan Duvdevani, Mordechai Landau, Ezekiel H. Pode, Dov |
author_facet | Gofrit, Ofer N. Yutkin, Vladimir Shapiro, Amos Pizov, Galina Zorn, Kevin C. Hidas, Guy Gielchinsky, Ilan Duvdevani, Mordechai Landau, Ezekiel H. Pode, Dov |
author_sort | Gofrit, Ofer N. |
collection | PubMed |
description | BACKGROUND: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette–Guerin (BCG). We compared the response, to treatment with BCG, of UC containing glandular, squamous, nested, and micropapillary types of differentiation to response of conventional non-muscle invasive high-grade UC. METHODS: A total of 100 patients were diagnosed with variant histology urothelial cancer between June 1995 and December 2013. Forty-one patients with Ta or T1, confirmed by second look biopsies, received immunotherapy with BCG. Fourteen patients in this group were diagnosed with micropapillary differentiation, 13 patients with squamous differentiation, 9 patients with glandular differentiation, and 7 patients with nested variants. The control group included 140 patients with conventional high-grade UC. Both groups have been treated and followed similarly. FINDINGS: Patients with variant tumors had similar clinical features to patients with conventional disease, including age, male to female ratio, stage, the presence of Tis, and median follow-up. Patients with variant tumors had a significantly worse prognosis compared to patients with conventional high-grade UC, including 5-year recurrence-free survival (63.5 Vs. 71.5%, p = 0.05), 5-year progression (≥T2)-free survival (60 Vs. 82.5%, p = 0.002), 5-year disease-specific survival (73 Vs. 92.5%, p = 0.0004), and overall survival (66 Vs. 89.5%, 0.05). INTERPRETATION: A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC. |
format | Online Article Text |
id | pubmed-4791377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47913772016-03-24 The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer Gofrit, Ofer N. Yutkin, Vladimir Shapiro, Amos Pizov, Galina Zorn, Kevin C. Hidas, Guy Gielchinsky, Ilan Duvdevani, Mordechai Landau, Ezekiel H. Pode, Dov Front Oncol Oncology BACKGROUND: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette–Guerin (BCG). We compared the response, to treatment with BCG, of UC containing glandular, squamous, nested, and micropapillary types of differentiation to response of conventional non-muscle invasive high-grade UC. METHODS: A total of 100 patients were diagnosed with variant histology urothelial cancer between June 1995 and December 2013. Forty-one patients with Ta or T1, confirmed by second look biopsies, received immunotherapy with BCG. Fourteen patients in this group were diagnosed with micropapillary differentiation, 13 patients with squamous differentiation, 9 patients with glandular differentiation, and 7 patients with nested variants. The control group included 140 patients with conventional high-grade UC. Both groups have been treated and followed similarly. FINDINGS: Patients with variant tumors had similar clinical features to patients with conventional disease, including age, male to female ratio, stage, the presence of Tis, and median follow-up. Patients with variant tumors had a significantly worse prognosis compared to patients with conventional high-grade UC, including 5-year recurrence-free survival (63.5 Vs. 71.5%, p = 0.05), 5-year progression (≥T2)-free survival (60 Vs. 82.5%, p = 0.002), 5-year disease-specific survival (73 Vs. 92.5%, p = 0.0004), and overall survival (66 Vs. 89.5%, 0.05). INTERPRETATION: A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC. Frontiers Media S.A. 2016-03-15 /pmc/articles/PMC4791377/ /pubmed/27014622 http://dx.doi.org/10.3389/fonc.2016.00043 Text en Copyright © 2016 Gofrit, Yutkin, Shapiro, Pizov, Zorn, Hidas, Gielchinsky, Duvdevani, Landau and Pode. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Gofrit, Ofer N. Yutkin, Vladimir Shapiro, Amos Pizov, Galina Zorn, Kevin C. Hidas, Guy Gielchinsky, Ilan Duvdevani, Mordechai Landau, Ezekiel H. Pode, Dov The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer |
title | The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer |
title_full | The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer |
title_fullStr | The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer |
title_full_unstemmed | The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer |
title_short | The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer |
title_sort | response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791377/ https://www.ncbi.nlm.nih.gov/pubmed/27014622 http://dx.doi.org/10.3389/fonc.2016.00043 |
work_keys_str_mv | AT gofritofern theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT yutkinvladimir theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT shapiroamos theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT pizovgalina theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT zornkevinc theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT hidasguy theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT gielchinskyilan theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT duvdevanimordechai theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT landauezekielh theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT podedov theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT gofritofern responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT yutkinvladimir responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT shapiroamos responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT pizovgalina responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT zornkevinc responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT hidasguy responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT gielchinskyilan responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT duvdevanimordechai responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT landauezekielh responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer AT podedov responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer |